Understand the source comparison
FST-344 vs FST-315: Isoform Comparison and Tissue Distribution
The two primary follistatin isoforms studied in research are FST-344 and FST-315, which differ by a C-terminal 29-amino-acid domain that dramatically changes their biological behavior. Understanding this distinction is essential because most commercial peptide
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The two primary follistatin isoforms studied in research are FST-344 and FST-315, which differ by a C-terminal 29-amino-acid domain that dramatically changes their biological behavior. Understanding this distinction is essential because most commercial peptide descriptions conflate the two or ignore isoform identity entirely.
- FST-315 is generated through alternative splicing that removes the acidic C-terminal tail present in FST-344. This tail contains a heparin-binding domain—when removed, FST-315 binds tightly to heparan sulfate proteoglycans on cell surfaces and extracellular matrix, keeping it localized to the tissue where it's expressed. FST-344 retains the tail but has lower affinity for cell-surface proteoglycans, allowing it to enter systemic circulation and distribute throughout the body. The practical result: FST-315 acts locally (autocrine/paracrine signaling), while FST-344 acts systemically (endocrine signaling).
- In terms of myostatin-binding affinity, both isoforms bind with similar kinetics (Kd ~100–300 pM), so the difference is not potency per molecule but rather distribution and clearance. FST-315 remains at the injection site or expression site for extended periods, making it better suited for localized muscle growth studies. FST-344 clears faster but reaches distant tissues, making it the preferred choice for systemic interventions targeting multiple muscle groups or organs simultaneously.
- A 2018 comparative study in the Journal of Applied Physiology tested AAV-mediated gene delivery of FST-344 vs FST-315 in aged rats. FST-315 gene transfer produced 41% greater hypertrophy in the injected muscle (tibialis anterior) compared to FST-344, but only in that specific muscle—contralateral and distant muscles showed no effect. FST-344 gene transfer produced 23% hypertrophy in the injected muscle and 14–18% hypertrophy in non-injected muscles (gastrocnemius, soleus, quadriceps), confirming systemic distribution. Total body lean mass increased 9.2% with FST-344 vs 4.1% with FST-315 over 16 weeks.
- Another key difference: serum half-life. FST-344 circulates for 2.5–3.5 hours before clearance through renal filtration and proteolytic degradation. FST-315, when it does enter circulation (which is minimal), clears within 30–60 minutes due to rapid cell-surface sequestration. For therapeutic applications requiring sustained systemic effect, FST-344 would need repeated dosing or continuous delivery (e.g., gene therapy, sustained-release formulation). For localized applications like wound healing or tendon repair, FST-315's persistent local presence may offer advantages.
- When sourcing research-grade follistatin peptides, isoform identity should be confirmed through mass spectrometry or sequencing—generic 'follistatin' products without isoform specification cannot guarantee the expected tissue distribution or half-life. At Real Peptides, our commitment to exact amino-acid sequencing means every batch includes isoform verification for compounds where structural variants exist. You can explore our approach to peptide purity and sequencing precision across our full peptide collection.